|
NRGBR003
|
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or w/o Carboplatin for Node+ or High-Risk Node- Triple-Neg Invasive Breast Cancer |
Open (affiliates only) |
|
NSABPB55
|
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo Versus Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy |
Open (affiliates only) |
|
S1501
|
S1501: Prospective Evaluation in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III |
Open (affiliates only) |
|
UW16029
|
Feasibility of delivering electronic health record (EHR)-based survivorship care plans and planning to cancer survivors in a community oncology practice |
Open (affiliates only) |
|
A011104
|
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer |
Open |
|
A011106
|
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study |
Open |
|
A011202
|
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
Open |
|
A011401
|
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
Open |
|
A011502
|
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As
Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial |
Open |
|
A211102
|
Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology after 12 months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention versus Placebo Control in Premenopausal Women |
Open |
|
A221505
|
Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction |
Open |
|
ADVL1622
|
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors |
Open |
|
AGCT1531
|
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors |
Open |
|
ALTE15N2
|
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study |
Open |
|
APEC1621B
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations |
Open |
|
APEC1621D
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors |
Open |
|
APEC1621F
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations |
Open |
|
APEC1621G
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations |
Open |
|
E2112
|
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer |
Open |
|
EA1131
|
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy VS Capecitabine in Patients with Residual Triple-Negative Basal Like Breast Cancer following Neoaduvant Chemotherapy |
Open |
|
EAI142
|
[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer |
Open |
|
EAY131
|
Molecular Analysis for Therapy Choice (MATCH) |
Open |
|
MA39
|
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast cancer |
Open |
|
RTOG1119
|
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer-A Collaborative Study of NRG Oncology and KrogPha |
Open |
|
RTOG1304
|
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy |
Open |
|
S1207
|
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer |
Open |
|
S1418
|
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 cm residual Invasive Cancer or Positive Lymph Node |
Open |
|
UW13043
|
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of AZD8186 in Patients with Advanced Castration resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB mutated/amplified Advanced Solid Malignancies, as Monotherapy and in Combination with Abiraterone Acetate or AZD2014 |
Open |
|
UW13056
|
Women's Integrative Sexual Health (WISH) Program Research Database |
Open |
|
UW13060
|
Pilot study of short-term bisphosphonate administration as chemopreventive for breast cancer via engagement of gamma-delta T cells |
Open |
|
UW13061
|
Pilot Study: Comparison of rpFNA and CNB for Breast Tissue Collection for Chemopreventive Studies |
Open |
|
UW13089
|
A Randomized Controlled Trial Evaluating the Impact of Pre-Operative Web-based Breast Cancer Information on the Quality of Patient Decision-Making |
Open |
|
UW14035
|
Correlation of tumorigenic properties in early stage breast cancer: an investigation of tumor types, mitotic phenotypes, and tumor microenvironment interactions
|
Open |
|
UW15026
|
Breast MR/PET Imaging Protocol Development and Validation |
Open |
|
UW15048
|
Monitoring microwave ablation of breast tumors via real-time microwave imaging |
Open |
|
UW15054
|
A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies |
Open |
|
UW15078
|
An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) |
Open |
|
UW15106
|
Genomic analysis of long-term survivors with metastatic cancer |
Open |
|
UW15114
|
A Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers with Nuclear Epidermal Growth Factor Receptor |
Open |
|
UW15128
|
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer) |
Open |
|
UW16005
|
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma |
Open |
|
UW16009
|
Treatment of Relapsed or Refractory Neuroblastoma with Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2 |
Open |
|
UW16044
|
A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024
|
Open |
|
UW16050
|
A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer |
Open |
|
UW16059
|
Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire |
Open |
|
UW16063
|
Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect |
Open |
|
UW16083
|
A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer |
Open |
|
UW16088
|
A randoMized phAse II trIal of fulvestraNt wiTh or without Ribociclib After progression on AntI-estrogeN therapy plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (MAINTAIN Trial) |
Open |
|
UW16106
|
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response |
Open |
|
UW16107
|
A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors |
Open |
|
UW16112
|
A Phase II Study of Neoadjuvant Weekly Carboplatin/Paclitaxel followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients with Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer |
Open |
|
UW16116
|
A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Rα)) alone and in combination with PDR001 in Adults with Metastatic Cancers |
Open |
|
UW16137
|
An Open-Label, Dose-Finding And Proof Of Concept Study Of The Pd-L1 Probody Therapeutic, Cx-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Anti-Pd-1/Pd-L1 Inhibitor Naïve Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas |
Open |
|
UW16141
|
Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
|
Open |
|
UW16151
|
Pharmacodynamic biomarkers of standard anti-microtubule drugs as assessed by early tumor biopsy
|
Open |
|
UW17034
|
[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer |
Open |
|
UW17038
|
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) |
Open |
|
UW17055
|
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors
|
Open |
|
UW17064
|
A Phase 2, Multi-center, Open Label Study of NIR-178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
|
Open |
|
UW17092
|
Intraoperative use of the OTIS (Optical Tissue Imaging System) in Surgically Excised Lumpectomy Breast Tissue
|
Open |
|
UW17098
|
Phase 1 Study of TTC-352 in Patients with Metastatic Breast Cancer Progressing on Endocrine Therapy
|
Open |
|
UW17120
|
An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA)
|
Open |
|
UW17125
|
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS: A Phase III Prospective Randomized Trial (AFT-25) |
Open |
|
UW17147
|
Pre-Visit Planning in Palliative Care |
Open |
|
UW17152
|
An Open-Label Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification
|
Open |
|
UW18036
|
Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations
|
Open |
UW Carbone
